Lymphoma Trial, Recruiting (NCT06774326)

Lymphoma Trial, Recruiting NCT06774326 Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06774326 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with Hodgkin's lymphoma or a type of blood cancer called diffuse large B-cell lymphoma (DLBCL)
People who are receiving a treatment plan that includes a type of chemotherapy drug known as anthracyclines
People aged 18 or older
People who have given their written agreement to take part in the trial

Who may not be able to join:

People for whom a CT scan or the dye used during CT scans (called iodinated contrast) is not safe — for example, those who are pregnant, or those with severely reduced kidney function who are not on dialysis (confirm with trial site for exact kidney function thresholds)
People who have a history of heart or cardiovascular problems, such as a previous heart attack, known blockages in the heart's arteries, heart failure, irregular heartbeats, previous inflammation of the heart muscle, or other heart muscle conditions
People who have previously had radiotherapy to the chest area (mediastinum)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vincenzo Russo, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phone: +390512144747

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06774326

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: +390512144747

More information: https://clinicaltrials.gov/study/NCT06774326

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with Hodgkin's lymphoma or a type of blood cancer called diffuse large B-cell lymphoma (DLBCL)
People who are receiving a treatment plan that includes a type of chemotherapy drug known as anthracyclines
People aged 18 or older
People who have given their written agreement to take part in the trial

Who may not be able to join:

People for whom a CT scan or the dye used during CT scans (called iodinated contrast) is not safe — for example, those who are pregnant, or those with severely reduced kidney function who are not on dialysis (confirm with trial site for exact kidney function thresholds)
People who have a history of heart or cardiovascular problems, such as a previous heart attack, known blockages in the heart's arteries, heart failure, irregular heartbeats, previous inflammation of the heart muscle, or other heart muscle conditions
People who have previously had radiotherapy to the chest area (mediastinum)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Registry

ClinicalTrials.gov

Start date

14 February 2024

Est. completion

1 August 2029

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Myocardial damage

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov